{"prompt": "['MC1752', '67', '16.321 Adverse Events: All eligible patients that have initiated treatment will be considered', 'evaluable for assessing adverse event rate(s). The maximum grade for each type of', 'adverse event will be recorded for each patient, and frequency tables will be', 'reviewed to determine patterns. Additionally, the relationship of the adverse event(s)', 'to the study treatment will be taken into consideration.', '16.322 Analysis of Patient-Reported Outcomes (EORTC QLQ-30, EORTCQOL-BLM30)', ':', 'Quality of life will be assessed at screening, at end of avelumab treatment, and EOS', '(12 month after registration). QOL will be measured using the EORTO QLQ-C30, a', '30-item patient-reported questionnaire about patient ability to function, symptoms', 'related to the cancer and its treatment, overall health and quality of life, and', 'perceived financial impact of the cancer and its treatment. 28 of the 30 items are', 'measured on a 1-4 scale (1=not at all; 4=very much) with the remaining two items', '(overall health and overall quality of life) scored on a 1-7 numeric analogue scale', '(1=very poor; 7=excellent). The recall period for the EORTC QLQ-C30 is one week.', 'The EORTC QLQ-C30 is the product of more than a decade of collaborative research', 'and to date, more than 2200 studies using the EORTC QLQ-C30 have been', 'registered with the EORTC (Fayers et al, 2001 [EORTC Scoring Manual]). The', 'EORTC QLQ-BLM30 is a 30-item questionnaire for patients with muscle invasive', 'bladder cancer (T2, T3, T4a and T4b). The muscle-invasive bladder cancer module', 'contains additional items assessing urostomy problems, problems associated with the', 'use of a catheter, and body image.', 'A paper booklet containing all the patient-reported outcomes will be administered in', 'clinic at baseline and every cycle visit at Mayo Clinic, and each PRO will be scored', 'according to the published scoring algorithm. Scale score trajectories over time will', 'be examined using stream plots and mean plots with standard deviation error bars', 'overall. Changes from baseline will be statistically tested using paired t-tests, and', 'standardized response means (mean of the change from baseline scores at a given', 'cycle, divided by the standard deviation of the change scores) will be interpreted', \"(after applying Middel's (2002) adjustment) using Cohen's (1988) cut-offs: <0.20 =\", 'trivial; 0.20-<0.50 = small; 0.50-<0.80 = moderate; and >=/0.80 = large. Correlation', 'between outcomes will employ Pearson and/or Spearman correlations at individual', 'time points.', '16.323 Progression-Free Survival (PFS): PFS will be defined as the time from registration', 'to time of first documentation of progression (as defined in Section 11.b) or death', 'due to any cause. Patients last known to be alive and not to have progressed are', 'censored at the last day of contact (or at study completion - 12 months). PFS rate at', '1 year will be estimated using the method of Kaplan-Meier (1958).', '16.324 Recurrence-Free Survival (RFS): RSF will be defined as the time from documented', 'complete response to the first documentation of recurrence (as defined in Section', '11.c). Patients last known to be alive and not to have recurred are censored at the last', 'day of contact (or at study completion - 12 months). RFS rate at 1 year will be', 'estimated using the method of Kaplan-Meier (1958),', '16.33', 'Exploratory & Correlative Endpoints: See section 2.3', 'Protocol Version Date: 21JUN2018']['MC1752', '68', '16.34', 'Translational analyses: Given the small sample size, all translational analyses are', 'considered exploratory and no adjustment for multiplicity will be employed. One-sided', 'p-values <0.10 are considered statistically significant throughout. Results will be used to', 'design subsequent confirmatory studies (likely as translational components within the', 'subsequent phase III study should this phase II study support the use of this combination', 'in a phase III study).', 'We will explore the relationship of PD-L1 (SP263 and SP142 ), CD8+ by IHC and tumor', 'mutational burden ( Foundation Medicine Panel) and clinical response in order to', 'identify if these markers may be predictive of response. Association of Bim', 'Expression will be evaluated at using the baseline tissue specimen and explored in', 'relation to 6 months post-registration response and subsequently in relation to other', 'clinical outcomes such as tumor response and adverse event incidence using two-way', \"tables and analyzed using Fisher's exact tests. Expression of immune signatures\", 'by', 'RNA-sequencing (RNA-seq) expression (using the baseline tissue specimen) will be', 'evaluated at baseline and explored in relation to clinical outcomes such as progression-', 'free survival, tumor response, and adverse event incidence using two-way tables and', \"box plots and analyzed using Fisher's exact tests or logistic regression methods, as\", 'appropriate.', '16.4', 'Data & Safety Monitoring', '16.41', 'The principal investigator(s) and the study statistician will review the study at', 'least twice a year to identify accrual, adverse event, and any endpoint problems', 'that might be developing. The Mayo Clinic Cancer Center (MCCC) Data Safety', 'Monitoring Board (DSMB) is responsible for reviewing accrual and safety data', 'for this trial at least twice a year, based on reports provided by the MCCC', 'Statistical Office.', '16.42', 'Adverse Event Stopping Rule: The stopping rule specified below is based on the', 'knowledge available at study development. We note that the Adverse Event', 'Stopping Rule may be adjusted in the event of either (1) the study re-opening to', 'accrual or (2) at any time during the conduct of the trial and in consideration of', 'newly acquired information regarding the adverse event profile of the', 'treatment(s) under investigation. The study team may choose to suspend accrual', 'because of unexpected adverse event profiles that have not crossed the', 'specified rule below.', 'Accrual will be temporarily suspended to this study if at any time we observe events', 'considered at least possibly related to study treatment (ie, an adverse event with attribute', 'specified as \"possible\", \"probable\", or \"definite\") that satisfy the following:', 'if 4 or more patients in the first 10 treated patients (or 40% after 20 patients', 'have been accrued) experience a Grade 3 or higher non-hematologic adverse', 'event.', 'Protocol Version Date: 21JUN2018']\n\n###\n\n", "completion": "END"}